Skip to content

NUTRAPHAR BE

Active
Private limited companyfounded 2024active for 2 yearsAvenue Baudouin de Changy 4, 1380 Lasne, BelgiumKBO/BCE: BE 1012.754.333
Summary

NUTRAPHAR BE has been active since 2024 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show negative equity (-€2,910) and a net result of -€7,910. Its solvency ranks better than 15% of 73 sector peers (NACE 21, financial year 2025). The computed 12-month bankruptcy probability is 1.0% (low).

Financials · financial year 2025, micro format

2025 annual accounts filed late (12 days) Filed on 12 August 2026, deadline 31 July 2026 (7 months after the close on 31 December 2025, Companies Code art. 3:10). Source: NBB, 2026-00396338.

Equity
-€2,910
Total assets
€1,779
Net result
-€7,910
Working capital
-€2,910

Turnover and EBIT margin not published: the micro format does not require them.

Key figures and ratios
2025 value
Debt
€4,689
Debt ≤ 1 year
€4,689
Ratios withheld: a balance sheet total of €1,779 is too small for a meaningful ratio.

Peer companies

Historical observation

Of the 7,639 companies that looked in July 2024 the way this one looks now, 8.8% went bankrupt within 24 months and 84.8% are still going.

  • Micro
  • 2 to 5 years old
  • negative equity
  • a loss of 10% of the balance sheet or more
8.8% went bankrupt
5.6% stopped otherwise
84.8% still going

A further 0.7% stopped, but we cannot tell whether within those 24 months.

For this company itself Checked computes a lower bankruptcy probability: 1.0% over twelve months. The score reads more about this company than the group's four characteristics; both figures are right about what they measure.

How reliable is this rule?

Tested on the year before, without using that year itself: the groups of July 2023 gave each of the 497,473 companies of July 2024 its group's bankruptcy share. Expected: 1.6%; actually bankrupt within 24 months: 1.7%.

The companies in ten equal groups, from lowest to highest expected share.
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 1.0%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 3.0% 3.1%
10 5.6% 6.2%

The rule ranks well: a company that went bankrupt got a higher share than one that kept going in 74.5% of comparisons. The level follows the economy: in a year with more bankruptcies, the actual share is higher than the year before.

An observation about 7,639 comparable companies, not a prediction for this company. The sector does not count: the register keeps no sector for companies that stopped, so it would make the outcome look better than it was.

Annual accounts
Filed annual accounts As filed with the NBB · 2025 · 23 lines
Balance sheet Code2025
Assets
Total assets20/58€1,779
Current assets29/58€1,779
Amounts receivable within one year40/41€688
Other amounts receivable41€688
Cash at bank and in hand54/58€1,091
Equity and liabilities
Total equity and liabilities10/49€1,779
Equity10/15-€2,910
Contributions10/11€5,000
Profit (loss) carried forward14-€7,910
Amounts payable17/49€4,689
Amounts payable within one year42/48€4,689
Trade debts44€295
Suppliers440/4€295
Other amounts payable47/48€4,394
Income statement Code2025
Other operating charges640/8€387
Gross operating margin9900-€7,450
Operating profit (loss)9901-€7,838
Financial charges65/66B€72
Recurring financial charges65€72
Profit (loss) for the period before taxes9903-€7,910
Profit (loss) for the period9904-€7,910
Profit (loss) for the period to be appropriated9905-€7,910
Appropriation of the result
Profit (loss) to be appropriated9906-€7,910

The notes to these accounts (1 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.

Line2025
Other operating charges640/8€387
Gross operating margin9900-€7,450
Operating profit (loss)9901-€7,838
Financial charges65/66B€72
Recurring financial charges65€72
Profit (loss) for the period before taxes9903-€7,910
Profit (loss) for the period9904-€7,910
Profit (loss) for the period to be appropriated9905-€7,910
Line2025
Assets
Total assets20/58€1,779
Current assets29/58€1,779
Amounts receivable within one year40/41€688
Other amounts receivable41€688
Cash at bank and in hand54/58€1,091
Equity and liabilities
Total equity and liabilities10/49€1,779
Equity10/15-€2,910
Contributions10/11€5,000
Profit (loss) carried forward14-€7,910
Amounts payable17/49€4,689
Amounts payable within one year42/48€4,689
Trade debts44€295
Suppliers440/4€295
Other amounts payable47/48€4,394
Line2025
Profit (loss) for the period9904-€7,910
Operating cash flow (approximation)-€7,910

Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.

Download as CSV

Filings with the National Bank (1)
Financial year Type Filed Reference
31-12-2025 micro format 12-08-2026 2026-00396338

Similar companies · same sector and region

This company's figures show no positive equity and no headcount, so a size comparison is not possible. These companies share only the sector and the region. Of the 97 active companies whose main activity is manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21209), figures are known for 74. See the whole sector

Public contracts: No European public contracts awarded found since October 2016. Contracts below the EU thresholds are not in TED.